

Melanoma staging undergoes evidencebased revision

20 October 2017



(HealthDay)—The American Joint Committee on Cancer (AJCC) melanoma staging system has been revised, according to a report published online Oct. 13 in *CA: A Cancer Journal for Clinicians*.

Jeffrey E. Gershenwald, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and <u>colleagues</u> from the AJCC Melanoma Expert Panel assembled a large database of >46,000 patients from 10 centers worldwide with stages I, II, and III melanoma diagnosed since 1998. Changes in the eighth edition Cancer Staging Manual were based upon analysis of this database.

Key changes include recording tumor thickness measurements to the nearest 0.1 mm; new definitions of T1a and T1b (T1a,

APA citation: Melanoma staging undergoes evidence-based revision (2017, October 20) retrieved 16 July 2022 from <u>https://medicalxpress.com/news/2017-10-melanoma-staging-evidence-based.html</u>



This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.